Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Molecular and Cellular Biology

Abstract 1153: TGFβR1 germline variant Int7G24A but not TGFβR1*6 increases risk for colon cancer

Julia H. Carter, Kevin Murray, Jonathan Bender, Hillary Restle, Shane Mulvihill, Bruce Colligan, James Deddens, James Schaeper and Larry Douglass
Julia H. Carter
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Murray
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Bender
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hillary Restle
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Mulvihill
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Colligan
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Deddens
2University of Cincinnati, Cincinnati, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Schaeper
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry Douglass
1Wood Hudson Cancer Research Lab., Newport, KY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2012-1153 Published April 2012
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL

Abstract

Transforming growth factor beta (TGF-β) regulates many processes associated with tumor initiation and progression including proliferation, differentiation, migration, cell survival, angiogenesis, and immunosurveillance. The TGF-β signal is transduced by a membrane-bound serine-threonine kinase receptor complex including TGF-β type I and type II receptors. Germline variations in the gene for transforming growth factor beta receptor 1(TGFβR1), a G-to-A single nucleotide polymorphism within intron 7 of the TGFβR1 gene called Int7G24A, and TGFβR1*6A, a nine base pair deletion that occurs in the coding region in exon 1 of the TGFβR1 gene, have been associated with progression and/or initiation of cancers of the kidney and bladder, lung, and breast; however, the association of TGFβR1*6A and Int7G24A with colon cancer is controversial. Approximately 141,000 new cases of colorectal cancer (CRC) will be diagnosed in the US during 2012 and there will be more than 69,000 CRC related deaths. Detection of CRC at early stages is the key to survival, hence we sought to determine a possible association of TGFβR1*6A and Int7G24A with CRC risk. These two germline variants in TGFβR1 were analyzed by capillary electrophoresis in DNA extracted from FFPE archived specimens of normal tissues from 253 patients with colorectal neoplasms and 219 patients who never developed any form of cancer. We found that 46.5% of patients with CIS (stage 0), 46.7% of patients with invasive CRC (Stages I & II) and 46.7% of patients with metastatic CRC (Stages III & IV) were carriers of Int7G24A, compared to 24.7% of patients without any cancer, and this difference was highly significant (p < 0.0001). In contrast the prevalence of Int7G24A in people with benign adenomas who never developed cancer (13.3%) did not differ significantly from non-cancer controls. TGFβR1*6A, was not associated with CRC at any stage compared to non-cancer controls (p = 0.2163). Importantly, the prevalence of TGFβR1*6A in benign adenoma patients that did not develop cancer was significantly higher (33.3%) than in patients with CIS (9.3%, p = 0.02) or metastatic CRC (12.0%, p = 0.03), a finding that is consistent with recent studies of human CRC reporting that tumors with TGFβR1*6A have a lower degree of genetic instability. Neither variant was associated significantly with reduced survival; however, nearly 75% of patients with TGFβR1*6A survived compared to 50% with Int7G24A. We conclude that Int7G24A is associated with increased risk for all stages of CRC whereas TGFβR1*6A is not. These results suggest that Int7G24A may be a biomarker to aid in identification of people at a higher risk for developing CRC thereby promoting CRC detection at early stages and increased CRC survival.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1153. doi:1538-7445.AM2012-1153

  • ©2012 American Association for Cancer Research
Back to top
Cancer Research: 72 (8 Supplement)
April 2012
Volume 72, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1153: TGFβR1 germline variant Int7G24A but not TGFβR1*6 increases risk for colon cancer
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 1153: TGFβR1 germline variant Int7G24A but not TGFβR1*6 increases risk for colon cancer
Julia H. Carter, Kevin Murray, Jonathan Bender, Hillary Restle, Shane Mulvihill, Bruce Colligan, James Deddens, James Schaeper and Larry Douglass
Cancer Res April 15 2012 (72) (8 Supplement) 1153; DOI: 10.1158/1538-7445.AM2012-1153

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1153: TGFβR1 germline variant Int7G24A but not TGFβR1*6 increases risk for colon cancer
Julia H. Carter, Kevin Murray, Jonathan Bender, Hillary Restle, Shane Mulvihill, Bruce Colligan, James Deddens, James Schaeper and Larry Douglass
Cancer Res April 15 2012 (72) (8 Supplement) 1153; DOI: 10.1158/1538-7445.AM2012-1153
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology

  • Abstract RAOS15-03: Pancreatic tumor stroma as a therapeutic target
  • Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
  • Abstract LB-298: The multiple-myeloma associated snoRNA, ACA11 increases oxidative stress and cell proliferation
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Molecular Markers

  • Abstract 1146: A functional polymorphism on chromosome 15q25 associated with survival of early stage non-small cell lung cancer
  • Abstract 1148: The relationship between the EMT status in primary lung adenocarcinomas and the DFS, and the results of the molecular analyses of lung adenocarcinoma with regard to the IGF1R and EMT status
  • Abstract 1163: HYAL4 is a novel potential prognostic and diagnostic biomarker for bladder cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement